SCHEMBL2028563

SCHEMBL2028563

CSc1cc(NC2CC2)n2ncc(/C=C3\NC(=O)NC3=O)c2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2B P67870 3/20 0.43
KDM4E B2RXH2 6/20 0.35
MAPT P10636 4/20 0.35
GAA P10253 2/20 0.35
GSK3B P49841 2/20 0.34
ALDH1A1 P00352 4/20 0.33
HPGD P15428 3/20 0.33
PKM P14618 1/20 0.33
RAB9A P51151 3/20 0.32
NPC1 O15118 2/20 0.32
MEN1 O00255 1/20 0.32
NR2F2 P24468 1/20 0.32
KMT2A Q03164 1/20 0.32
LMNA P02545 2/20 0.32
CSNK2A2 P19784 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
POLB P06746 1/20 0.31
NCOA1 Q15788 1/20 0.31
NCOA3 Q9Y6Q9 1/20 0.31
CSNK2A1 P68400 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2028565 1.00 CSNK2B (0.43) CSNK2BKDM4EMAPTGAAGSK3B
SCHEMBL2028567 1.00 CSNK2B (0.43) CSNK2BKDM4EMAPTGAAGSK3B
SCHEMBL12645378 0.85 CSNK2B (0.46) CSNK2BKDM4EMAPTGAAGSK3B
SCHEMBL2028226 0.85 CSNK2B (0.46) CSNK2BKDM4EMAPTGAAGSK3B
SCHEMBL6930949 0.85 CSNK2B (0.46) CSNK2BKDM4EMAPTGAAALDH1A1
SCHEMBL17641203 0.85 CSNK2B (0.46) CSNK2BKDM4EMAPTGAAALDH1A1
SCHEMBL2028224 0.85 CSNK2B (0.46) CSNK2BKDM4EMAPTGAAGSK3B
SCHEMBL1935775 0.85 CSNK2B (0.46) CSNK2BKDM4EMAPTGAAGSK3B
SCHEMBL14158302 0.84 CSNK2A1 (0.41) CSNK2BGAAGSK3BRAB9ANPC1
SCHEMBL14158298 0.84 CSNK2A1 (0.41) CSNK2BGAAGSK3BRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2509602-B9 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-11-01 EP disclosed
EP-2509602-B1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-01-25 EP disclosed
US-9303033-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2016-04-05 US disclosed
US-9303033-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2016-04-05 US disclosed
US-9303033-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2016-04-05 US disclosed
US-8575177-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2013-11-05 US disclosed
US-8575177-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2013-11-05 US disclosed
US-8575177-B2 Pyrazolopyrimidines and related heterocycles as CK2 inhibitors SENHWA BIOSCIENCES, INC. (TW) 2013-11-05 US disclosed
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-23 US disclosed
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-23 US disclosed
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152240-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CDK2, CKS2, CSNK2A1 CSNK2B 13/4885KDM4E 2647/4885MAPT 2912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.